Rawpixel / Shutterstock.com
Philip Johnson, Johnson & Johnson’s senior vice president of intellectual property and policy, told the BIO International Convention yesterday that uncertainty around patent eligibility of inventions is a “silent killer of innovation”.
If you have already subscribed please login.
If you have any technical issues please email tech support.
BIO 2015, Johnson & Johnson, Sequenom, patent eligibility, diagnostic patents, BIO International Convention 2015, David Kappos
